Parkinson’s disease (PD) is the second commonest neurodegenerative disorder in the older adult and is characterized by progressive disabling motor symptoms of bradykinesia, tremor, rigidity, postural instability and also non motor symptoms that affect quality of life. The pharmacotherapy of PD consists of oral, transdermal, and subcutaneous medications, as well as invasive advanced therapies at later stages of the disease. PD medications are often started as monotherapy but with the progression of the illness often there is a need to add more medications and frequently comprises of a challenging polypharmacotherapy. Adverse effects of pharmacotherapy often add to the problems of adequate treatment. Patients and physicians have to prioritize treatment goals on the most disabling symptoms and the safest and most effective treatments. Almost every year newer medications and modes of delivery continue to be researched and added to the therapeutic armamentarium. This review article outlines existing and emerging pharmacotherapies for motor symptoms in PD.

帕金森氏病 (PD) 是老年人中第二常见的神经退行性疾病，其特征是运动迟缓、震颤、僵硬、姿势不稳定等进行性致残运动症状，以及影响生活质量的非运动症状。PD 的药物治疗包括口服、透皮和皮下药物治疗，以及疾病后期的侵入性晚期治疗。PD 药物通常作为单一疗法开始，但随着疾病的进展，通常需要添加更多药物，并且通常包括具有挑战性的多种药物疗法。药物治疗的副作用常常增加了充分治疗的问题。患者和医生必须优先考虑最致残的症状和最安全、最有效的治疗方法。几乎每年都会继续研究更新的药物和给药方式，并将其添加到治疗设备中。这篇综述文章概述了针对 PD 运动症状的现有和新兴药物疗法。